Compare · AMGN vs TVGN
AMGN vs TVGN
Side-by-side comparison of Amgen Inc. (AMGN) and Tevogen Bio Holdings Inc. (TVGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AMGN and TVGN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- AMGN is the larger of the two at $223.19B, about 4820.9x TVGN ($46.3M).
- Over the past year, AMGN is up 48.0% and TVGN is down 83.7% - AMGN leads by 131.7 points.
- Both names hit the wire about 4 times in the past 4 weeks.
- AMGN has more recent analyst coverage (25 ratings vs 2 for TVGN).
- Company
- Amgen Inc.
- Tevogen Bio Holdings Inc.
- Price
- $440.00+3.22%
- $6.05-20.75%
- Market cap
- $223.19B
- $46.3M
- 1M return
- +16.88%
- -21.36%
- 1Y return
- +47.95%
- -83.74%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1983
- 2022
- News (4w)
- 4
- 4
- Recent ratings
- 25
- 2
Amgen Inc.
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and a strategic research and development collaboration with Neumora Therapeutics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Latest AMGN
- FDA Approval for REPATHA issued to AMGEN INC
- FDA Approval for RIABNI issued to AMGEN INC
- KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034
- AMGEN ANNOUNCES POSITIVE TOPLINE PHASE 3 RESULTS FOR DAZODALIBEP IN MODERATE-TO-SEVERE SYSTEMIC SJÖGREN'S DISEASE
- FDA Approval for IMDELLTRA issued to AMGEN INC
- FDA APPROVES REDUCED MONITORING TIME FOR FIRST TWO DOSES OF IMDELLTRA®
- AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
- IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- Amgen downgraded by BMO Capital Markets with a new price target
- New insider Dittrich Thomas J.W. claimed ownership of 16,860 shares (SEC Form 3)
Latest TVGN
- UPDATE – Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
- Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
- Tevogen Bio Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
- Chief Executive Officer Saadi Ryan H. was granted 8,000,000 shares, increasing direct ownership by 216% to 11,705,689 units (SEC Form 4)
- Chief Financial Officer Desai Kirti was granted 750,000 shares, increasing direct ownership by 309% to 992,983 units (SEC Form 4)
- Tevogen Bio Holdings Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Director Goh Keow Lin was granted 75,000 shares, increasing direct ownership by 154% to 123,678 units (SEC Form 4)
- Director Podlogar Susan M was granted 75,000 shares, increasing direct ownership by 154% to 123,678 units (SEC Form 4)
- Director Sordillo Victor J. was granted 75,000 shares, increasing direct ownership by 146% to 126,539 units (SEC Form 4)